Humana (NYSE:HUM) Stock Price Expected to Rise, Barclays Analyst Says

Humana (NYSE:HUM) had its price objective upped by Barclays from $270.00 to $322.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s target price indicates a potential upside of 9.16% from the company’s previous close.

A number of other research firms also recently weighed in on HUM. Truist Financial upped their target price on Humana from $290.00 to $325.00 and gave the stock a “hold” rating in a report on Friday. Guggenheim initiated coverage on Humana in a report on Wednesday. They issued a “buy” rating and a $326.00 price objective for the company. Morgan Stanley reduced their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Mizuho lifted their price target on shares of Humana from $305.00 to $316.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average target price of $288.60.

Humana Trading Up 1.6 %

Shares of NYSE:HUM traded up $4.72 during midday trading on Friday, hitting $294.97. 1,246,021 shares of the stock traded hands, compared to its average volume of 1,747,977. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business’s 50 day moving average is $265.56 and its two-hundred day moving average is $270.77. The stock has a market capitalization of $35.60 billion, a PE ratio of 29.65, a P/E/G ratio of 2.05 and a beta of 0.62. Humana has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts forecast that Humana will post 16.47 earnings per share for the current year.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently bought and sold shares of HUM. Dodge & Cox lifted its position in shares of Humana by 106.7% in the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after buying an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. increased its stake in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the last quarter. Norges Bank bought a new position in shares of Humana during the 4th quarter valued at approximately $416,202,000. Pzena Investment Management LLC grew its holdings in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after purchasing an additional 1,103,132 shares in the last quarter. Finally, Boston Partners increased its position in Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after purchasing an additional 893,637 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.